SYM FINANCIAL Corp Acquires Shares of 1,107 Zoetis Inc. (NYSE:ZTS)

SYM FINANCIAL Corp bought a new position in Zoetis Inc. (NYSE:ZTS) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,107 shares of the company’s stock, valued at approximately $218,000.

Other large investors have also modified their holdings of the company. River Street Advisors LLC grew its position in shares of Zoetis by 3.4% in the 4th quarter. River Street Advisors LLC now owns 1,757 shares of the company’s stock worth $347,000 after acquiring an additional 58 shares in the last quarter. Perigon Wealth Management LLC increased its stake in Zoetis by 0.3% during the fourth quarter. Perigon Wealth Management LLC now owns 23,581 shares of the company’s stock valued at $4,654,000 after purchasing an additional 59 shares during the last quarter. Revolve Wealth Partners LLC raised its holdings in shares of Zoetis by 5.0% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,281 shares of the company’s stock worth $253,000 after purchasing an additional 61 shares during the period. Ellevest Inc. lifted its position in shares of Zoetis by 2.4% in the 3rd quarter. Ellevest Inc. now owns 2,790 shares of the company’s stock worth $485,000 after buying an additional 66 shares during the last quarter. Finally, Atria Wealth Solutions Inc. boosted its holdings in shares of Zoetis by 0.4% in the 3rd quarter. Atria Wealth Solutions Inc. now owns 15,975 shares of the company’s stock valued at $2,779,000 after buying an additional 70 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS traded down $0.16 during trading hours on Friday, reaching $167.07. 3,007,125 shares of the company’s stock traded hands, compared to its average volume of 4,607,073. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The business’s fifty day simple moving average is $168.88 and its two-hundred day simple moving average is $178.84. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00. The firm has a market capitalization of $76.41 billion, a price-to-earnings ratio of 32.19, a P/E/G ratio of 2.62 and a beta of 0.86.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, beating the consensus estimate of $1.34 by $0.04. The firm had revenue of $2.19 billion for the quarter, compared to analysts’ expectations of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.74%. Zoetis’s quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter last year, the company earned $1.31 EPS. Analysts predict that Zoetis Inc. will post 5.78 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be given a $0.432 dividend. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a yield of 1.03%. Zoetis’s dividend payout ratio (DPR) is 33.33%.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 363 shares of Zoetis stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $197.74, for a total value of $71,779.62. Following the transaction, the executive vice president now owns 20,417 shares of the company’s stock, valued at approximately $4,037,257.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders sold 2,209 shares of company stock valued at $371,293. 0.16% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms recently weighed in on ZTS. Stifel Nicolaus dropped their price objective on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday. Piper Sandler reiterated an “overweight” rating and set a $195.00 price target (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Barclays reduced their price objective on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research report on Tuesday, April 23rd. The Goldman Sachs Group increased their target price on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Finally, StockNews.com downgraded shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $216.13.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.